Literature DB >> 3533755

Comparison of oral treatment of uncomplicated urogenital and rectal gonorrhoea with cefuroxime axetil ester or clavulanic acid potentiated amoxycillin (Augmentin).

R Schift, J van Ulsen, M C Ansink-Schipper, T van Joost, M F Michel, R K Woudstra, E Stolz.   

Abstract

In a randomised study of two drugs for the oral treatment of uncomplicated urogenital and rectal gonorrhoea the therapeutic effect of cefuroxime axetil ester (CAE) and amoxycillin plus clavulanic acid (A + C) was compared. Cefuroxime axetil ester 1.5 g was given to 129 men and 118 women. Amoxycillin 3.0 g and clavulanic acid 0.25 g was given to 131 men and 122 women. Both treatments were combined with probenecid 1.0 g and administered in a single oral dose. Of the 500 patients thus treated, 376 were assessable. In the group taking CAE, failure rates were 0.9% for the men and 0% for the women; and the overall failure rate was 0.5%. In the group taking A + C the equivalent failure rates were 4.6%, 1.2%, and 3.1%. The differences were not significant. Penicillinase producing Neisseria gonorrhoeae (PPNG) was isolated from 5.6% of the assessable patients. All 10 PPNG infections in the group taking CAE and four of 11 PPNG infections in the group taking A + C were cured. These numbers were too small to draw a definite conclusion about the efficacy of both drugs in this type of infection. Postgonococcal urethritis was observed in 35% of the men in the group taking CAE and in 32% of those in the group taking A + C. Side effects were noted in 38% of the group taking CAE and 28% of the group taking A + C. Nausea and vomiting were more commonly observed in the group taking CAE; and diarrhoea was more commonly observed in the group taking A + C.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3533755      PMCID: PMC1011983          DOI: 10.1136/sti.62.5.313

Source DB:  PubMed          Journal:  Genitourin Med        ISSN: 0266-4348


  8 in total

1.  The pharmacokinetics of orally absorbed cefuroxime compared with amoxycillin/clavulanic acid.

Authors:  R Wise; S A Bennett; J Dent
Journal:  J Antimicrob Chemother       Date:  1984-06       Impact factor: 5.790

2.  Antibiotic sensitivities of gonococci isolated in Rotterdam and results of treatment with cefuroxime.

Authors:  K C Nayyar; M F Michel; E Stolz
Journal:  Br J Vener Dis       Date:  1980-08

3.  Inhibition of beta-lactamase in penicillinase producing gonococci by clavulanic acid.

Authors:  B Van Klingeren; L J Van Wijngaarden
Journal:  J Antimicrob Chemother       Date:  1981-07       Impact factor: 5.790

4.  The combination of clavulanic acid and amoxycillin (Augmentin) in the treatment of patients infected with penicillinase producing gonococci.

Authors:  G A De Koning; D Tio; J F Coster; R A Coutinho; M C Ansink-Schipper
Journal:  J Antimicrob Chemother       Date:  1981-07       Impact factor: 5.790

5.  Epidemiology of PPNG infections in Amsterdam: analysis by auxanographic typing and plasmid characterisation.

Authors:  M C Ansink-Schipper; M H Huikeshoven; R K Woudstra; B van Klingeren; G A de Koning; D Tio; F J Schoonhoven; R A Coutinho
Journal:  Br J Vener Dis       Date:  1984-02

6.  Infections with non-penicillinase-producing Neisseria gonorrhoeae treated with cefuroxime: treatment failures.

Authors:  D de Hoop; K C Nayyar; B van Klingeren; E Stolz; M F Michel
Journal:  Sex Transm Dis       Date:  1982 Oct-Dec       Impact factor: 2.830

7.  Treatment of non-complicated urogenital, rectal and oropharyngeal gonorrhoea with intramuscular cefotaxime 1.0 g or cefuroxime 1.5 g.

Authors:  E Stolz; L Ong; T van Joost; M F Michel
Journal:  J Antimicrob Chemother       Date:  1984-09       Impact factor: 5.790

8.  Single dose oral amoxycillin 3 g with either 125 mg or 250 mg clavulanic acid to treat uncomplicated anogenital gonorrhoea.

Authors:  A G Lawrence; D C Shanson
Journal:  Genitourin Med       Date:  1985-06
  8 in total
  8 in total

1.  Cefuroxime axetil to treat gonorrhea.

Authors:  R P Das; K Jones; A J Robinson; D J Timmins
Journal:  Genitourin Med       Date:  1988-12

2.  Different doses of cefetamet pivoxil (Ro 15-8075) in the treatment of acute uncomplicated gonococcal urethritis in men.

Authors:  T T Tio; I R Sindhunata; J H Wagenvoort; M F Michel; E Stolz
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

Review 3.  Cefuroxime axetil: an updated review of its use in the management of bacterial infections.

Authors:  L J Scott; D Ormrod; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 4.  Amoxicillin/clavulanic acid. An update of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  P A Todd; P Benfield
Journal:  Drugs       Date:  1990-02       Impact factor: 9.546

Review 5.  Cephalosporin-probenecid drug interactions.

Authors:  G R Brown
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

Review 6.  Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  C M Perry; R N Brogden
Journal:  Drugs       Date:  1996-07       Impact factor: 9.546

7.  Proposed interpretive criteria and quality control parameters for testing susceptibility of Neisseria gonorrhoeae to beta-lactam-clavulanate combinations.

Authors:  P C Fuchs; A L Barry; C N Baker; P R Murray; J A Washington
Journal:  J Clin Microbiol       Date:  1992-08       Impact factor: 5.948

8.  Cefuroxime axetil (ceftin): a brief review.

Authors:  R D Leder; D S Carson
Journal:  Infect Dis Obstet Gynecol       Date:  1997
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.